newsfilter
← Latest News
Business Wire·

bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells

BIAFBIAFW
  • bioAffinity Technologies, Inc. will present preclinical findings at the 2026 RNA Therapeutics Symposium (June 24-26) regarding a novel topical siRNA therapy for squamous cell & basal cell carcinoma.
  • The research demonstrates that siRNAs targeting cell surface receptors CD320 & LRP2 selectively kill squamous & basal skin cancer cells in vitro while leaving non-cancerous skin cells unharmed.
  • An estimated 5.4 million cases of these skin cancers occur annually in the U.S., & current standard surgery often requires additional intervention due to incomplete resection or recurrence risks.
  • No commercial topical siRNA therapy is currently indicated for basal cell or squamous cell carcinoma.
  • The discovery is protected by U.S. Patent No. 12,305,171, issued in 2025, covering compositions & methods for treating cancer.
  • In vitro studies showed significantly impaired cancer cell proliferation following receptor silencing, with microscopic analysis confirming cytotoxicity without harm to healthy cells.
  • The findings remain preclinical & untested in humans, with no Investigational New Drug (IND) application filed with the FDA.
  • bioAffinity Technologies also markets CyPath® Lung, a noninvasive Laboratory Developed Test (LDT) for early lung cancer detection using flow cytometry & AI.
  • Forward-looking statements in the release warn that preclinical results may not replicate in human trials & regulatory approval is uncertain.